# iLab Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ilab-co

- Industry: Pharmaceuticals
- Headquarters: Seongnam-si,, South Korea
- Website: www.ilab.co.kr
- Total disclosed funding: $36M
- Latest round: Series B (Jun 1, 2021)
- Investors on record: 9

## About

Based in Seongnam-si, South Korea, and founded in 2017, iLab Co., Ltd. is a drug discovery company developing immune response-modulating small-molecule medications to fill gaps in the available therapy alternatives. The company is focusing on creating an oral small-molecule tumor necrosis factor (TNF), which will allow doctors to prescribe low immunogenicity medications to treat rheumatoid arthritis and other related conditions.

## Funding rounds

- Series B, Jun 1, 2021, $28M — Atinum Investment, IMM Investment, Company K Partners, Mirae Asset Venture Investment, Prodigy Investment, Krossroad Partners, K2Partners, Mirae Asset Capital
- Series A, Jun 28, 2018, $8.5M — Atinum Investment, Mirae Asset Venture Investment, Synergy IB Investment, Mirae Asset Capital

## Investors

- Atinum Investment (https://capitalatlas.ai/funds/atinum-investment) — Series A, Series B
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series A, Series B
- Synergy IB Investment (https://capitalatlas.ai/funds/synergy-ib-investment) — Series A
- Mirae Asset Capital (https://capitalatlas.ai/funds/mirae-asset-capital) — Series A, Series B
- IMM Investment (https://capitalatlas.ai/funds/imm-investment) — Series B
- Company K Partners (https://capitalatlas.ai/funds/company-k-partners) — Series B
- Prodigy Investment (https://capitalatlas.ai/funds/prodigy-investment) — Series B
- Krossroad Partners (https://capitalatlas.ai/funds/krossroad-partners) — Series B
- K2Partners — Series B